IMA Clinical Research nominated for Best Clinical Trial Network at 18th Annual Vaccine Industry Excellence (ViE) Awards 2025

18th Annual Vaccine Industry Excellence (ViE) Awards to celebrate outstanding achievements in vaccine industry

IMA Clinical Research is honored to be nominated for the 18th Annual Vaccine Industry Excellence (ViE) Awards 2025 as one of the best Clinical Trial Networks performing vaccine research. This prestigious award will be conferred at the World Vaccine Congress Washington, DC event on April 22, 2025.

The ViE Awards celebrate the vaccine industry’s most outstanding achievements over the past 12 months.  With 12 award categories, these awards have been created to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry between 2024-2025.

IMA Clinical Research is a physician-founded network specializing in Phase II-IV clinical trials with a focus on vaccines, T2DM, obesity, MASH, CVD, CNS and General Medicine. Our documented vaccine trial successes highlight our long-standing commitment to developing new, safe and effective disease-preventing treatments.

At IMA Clinical Research we strive to innovate, expedite and contribute exceptional results through rapid startup, balanced enrollment and delivery of quality data. Our proven track record to meet and exceed enrollment targets in vaccine trials across more than 15 disease models (e.g., COVID-19, Ebola, Influenza, Lyme’s, Norovirus, pneumonia, and RSV, etc.) is testimony that our efforts work.

We appreciate the recognition in support of our 2024-2025 vaccine trial achievements and look forward to seeing you at World Vaccine Congress in Washington, DC.